ロード中...
Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients
PURPOSE: Umeclidinium/vilanterol (UMEC/VI) is a novel fixed dose combination of a long-acting muscarinic receptor antagonist (LAMA) and a long-acting beta 2 receptor antagonist (LABA) agent. This analysis evaluated the incremental cost-effectiveness ratio (ICER) of UMEC/VI compared with tiotropium (...
保存先:
| 出版年: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2016
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4723026/ https://ncbi.nlm.nih.gov/pubmed/26848262 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S94006 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|